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C L I N I C A L I N Q U I R I E S
F R O M T H E F A M I L Y P R A C T I C E I N Q U I R I E S N E T W O R K
When should acute nonvenereal conjunctivitis
be treated with topical antibiotics?
EVIDENCE-BASED ANSWER
Children with suspected or culture-proven acute
nonvenereal bacterial conjunctivitis should be treated
with topical antibiotics, which hastens clinical and
microbiological remission and may prevent poten-
tially serious morbidity. In light of recent evidence
regarding the self-limiting nature of conjunctivitis in
adults and the development of antibiotic resistance, a
“wait-and-see” approach with careful follow-up may
be reasonable for adults, but this approach has not
been evaluated. (Grade of recommendation: C,
based on extrapolation from systematic reviews of
specialty clinic trials and cohort studies.)
EVIDENCE SUMMARY
Conjunctivitis accounts for 1% to 2% of office visits to
primary care practitioners.1 Conjunctivitis is more
commonly caused by bacteria in children (50% in 1
study2) than in adults, in whom viral conjunctivitis
predominates.3 Treating suspected or culture-proven
acute bacterial conjunctivitis with topical antibiotics
significantly shortens the clinical course of the disease
and results in higher microbiological cure rates than
placebo.1,4,5 A meta-analysis of 3 trials based in special-
ty clinics or hospitals reported significant clinical cure
or improvement of bacterial conjunctivitis with 2 to 5
days of topical antibiotics compared with placebo (RR
= 1.31, 95% CI, 1.11-1.55, number needed to treat = 5).1
Other articles have reported corneal or systemic com-
plications of bacterial conjunctivitis. For example, 
1 review reports that 25% of children with
Haemophilus influenzae conjunctivitis develop otitis
media.2
Although there is a small risk of complications and
longer time course when bacterial conjunctivitis is left
untreated, the disease is often self-limited, with a 64%
clinical remission rate in patients treated for 2 to 5 days
with placebo.1 The rate of spontaneous remission is
much higher for adults than for children (71.6% vs
28%, respectively). The Cochrane meta-analysis
reported a similar clinical cure rate in children for 6 to
10 days of treatment with topical antibiotics versus
placebo. A systematic review of 5 placebo-controlled
RCTs reported no serious adverse outcomes in con-
junctivitis patients regardless of treatment group.4 
Antibiotic resistance is a growing problem. Studies
of fluoroquinolone resistance rates report a range of
4% to 50% for ocular bacteria.6 The 50% resistance
rate occurred after 4 weeks of topical treatment in
postcataract surgery patients.
Overall, this evidence suggests that for adults,
watchful waiting rather than initially treating with
antibiotics is reasonable, given the self-limited nature
and lack of serious outcomes in untreated patients as
well as growing concern about antibiotic resistance.
Note that this recommendation applies only to acute
nonvenereal conjunctivitis. It is generally accepted
that conjunctivitis caused by gonococcus or chlamy-
dia should be suspected in all newborns and in
severe cases in sexually active young adults. These
cases warrant culturing and antibiotic treatment to
prevent serious complications.7
RECOMMENDATIONS FROM OTHERS
The American Optometric Association consensus
guideline states that ideal treatment should be based
on the specific causative organism. The guideline
concludes that treatment of bacterial conjunctivitis
with antibiotics can reduce symptoms, duration of ill-
ness, and chances of recurrence.8
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